Imaging pulmonary inflammation with positron emission tomography: A biomarker for drug development

Molecular Pharmaceutics

Volumn 3, Issue 5, 2006, Pages 488-495

  Chen, Delphine L ^a,b   Schuster, Daniel P ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Drug evaluation; Fluorodeoxyglucose; Lung inflammation; Positron emission tomography; Preclinical drug evaluation

Indexed keywords

ANTIINFLAMMATORY AGENT; BIOLOGICAL MARKER; E 5564; FLUORODEOXYGLUCOSE F 18; PLACEBO; UNCLASSIFIED DRUG;

CLINICAL TRIAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC IMAGING; DRUG DEVELOPMENT; DRUG MECHANISM; DRUG UPTAKE; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HUMAN; NEUTROPHIL; PNEUMONIA; PRIORITY JOURNAL; REVIEW;

BIOLOGICAL MARKERS; FLUORODEOXYGLUCOSE F18; HUMANS; PNEUMONIA; POSITRON-EMISSION TOMOGRAPHY;

EID: 33750383742     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp060050w     Document Type: Review

References (48)

1. Sagel, S.; Kapsner, R.; Osberg, I.; Sontag, M.; Accurso, F. Airway Inflammation in Children with Cystic Fibrosis and Healthy Children Assessed by Sputum Induction. Am. J. Respir. Crit. Care Med. 2001, 164 (8), 1425-1431.
2. Henig, N. R.; Tonelli, M. R.; Pier, M. V.; Burns, J. L.; Aitken, M. L. Sputum induction as a research tool for sampling the airways of subjects with cystic fibrosis. Thorax 2001, 56 (4), 306-311.
3. Rosenbluth, D.; Brody, S. Cystic Fibrosis. In Principles of Molecular Medicine; Jameson, J., Ed.; Humana Press: Totowa, NJ, 1998; pp 329-338.
4. Richard, J. C.; Chen, D. L.; Ferkol, T.; Schuster, D. P. Molecular imaging for pediatric lung diseases. Pediatr. Pulmonol. 2004, 37 (4), 286-296.
5. Love, C.; Palestro, C. Radionuclide imaging of infection. J. Nucl. Med. Technol. 2004, 32, 47-57.
6. Rennen, H. J.; Boerman, O. C.; Oyen, W. J.; Corstens, F. H. Imaging infection/inflammation in the new millennium. Eur. J. Nucl. Med. 2001, 28, 241-252.
7. Rennen, H. J.; Boerman, O. C.; Oyen, W. J.; Corstens, F. H. Molecular imaging of infection and inflammation. In Molecular nuclear medicine; Feinendegen, L. E., Shreeve, W. W., Eckelman, W. C., Bahk, Y.-W., Wagner, H. N., Jr., Eds.; Springer-Verlag: Berlin, 2003; pp 233-251.
8. Chatziioannou, A. F. Molecular imaging of small animals with dedicated PET tomographs. Eur. J. Nucl. Med. 2002, 29, 98-114.
9. Alavi, A.; Gupta, N.; Alberini, J. L.; Hickeson, M.; Adam, L. E.; Bhargava, P.; Zhuang, H. Positron emission tomography imaging in nonmalignant thoracic disorders. Semin. Nucl. Med. 2002, 32 (4), 293-321.
10. Pauwels, E. K.; Sturm, E. J.; Bombardieri, E.; Cleton, F. J.; Stokkel, M. P. Positron-emission tomography with [18F]fluorodeoxyglucose. J. Cancer Res. Clin. Oncol. 2000, 126, 549-559.
11. Zhuang, H.; Yu, J. Q.; Alavi, A. Applications of fluorodeoxyglucose-PET imaging in the detection of infection and inflammation and other benign disorders. Radiol. Clin. North Am. 2005, 43 (1), 121-34.
12. Stumpe, K. D.; Dazzi, H.; Schaffner, A.; von Schulthess, G. K. Infection imaging using whole-body FDG-PET. Eur. J. Nucl. Med. 2000, 27 (7), 822-832.
13. Sugawara, Y.; Braun, D. K.; Kison, P. V.; Russo, J. E.; Zasadny, K. R.; Wahl, R. L. Rapid detection of human infections with fluorine-18 fluorodeoxyglucose and positron emission tomography: preliminary results. Eur. J. Nucl. Med. 1998, 25 (9), 1238-1243.
14. Meller, J.; Strutz, F.; Siefker, U.; Scheel, A.; Sahlmann, C. O.; Lehmann, K.; Conrad, M.; Vosshenrich, R. Early diagnosis and follow-up of aortitis with [(18)F]FDG PET and MRI. Eur. J. Nucl. Med. Mol. Imaging 2003, 30 (5), 730-736.
15. Manthey, N.; Reinhard, P.; Moog, F.; Knesewitsch, P.; Hahn, K.; Tatsch, K. The use of [18 F]fluorodeoxyglucose positron emission tomography to differentiate between synovitis, loosening and infection of hip and knee prostheses. Nucl. Med. Commun. 2002, 23 (7), 645-653.
16. Zhou, Z.; Kozlowski, J.; Goodrich, A. L.; Markman, N.; Chen, D. L.; Schuster, D. P. Molecular imaging of lung glucose uptake after endotoxin in mice. Am. J. Physiol. 2005, 289 (5), L760-L768.
17. Chen, D. L.; Schuster, D. P. Positron emission tomography with [18F]fluorodeoxyglucose to evaluate neutrophil kinetics during acute lung injury. Am. J. Physiol. 2004, 286 (4), L834-L840.
18. Jones, H.; Schofield, J.; Krausz, T.; Boobis, A.; Haslett, C. Pulmonary fibrosis correlates with duration of tissue neutrophil activation. Am. J. Respir. Crit. Care Med. 1998, 158 (2), 620-628.
19. Hartwig, W.; Carter, E. A.; Jimenez, R. E.; Jones, R.; Fischman, A. J.; Fernandez-Del Castillo, C.; Warshaw, A. L. Neutrophil metabolic activity but not neutrophil sequestration reflects the development of pancreatitis-associated lung injury. Crit. Care Med. 2002, 30 (9), 2075-2082.
20. Jones, H.; Clark, R.; Rhodes, C.; Schofield, J.; Krausz, T.; Haslett, C. In vivo measurement of neutrophil activity in experimental lung inflammation. Am. J. Respir. Crit. Care Med. 1994, 149 (6), 1635-1639.
21. Hansson, L.; Ohlsson, T.; Valind, S.; Sandell, A.; Luts, A.; Jeppsson, B.; Wollmer, P. Glucose utilisation in the lungs of septic rats. Eur. J. Nucl. Med. 1999, 26 (10), 1340-1344.
22. Chen, D. L.; Ferkol, T. W.; Mintun, M. A.; Pittman, J. E.; Rosenbluth, D. B.; Schuster, D. P. Quantifying Pulmonary Inflammation in Cystic Fibrosis with Positron Emission Tomography. Am. J. Respir. Crit. Care Med. 2006, 173 (12), 1363-1369.
23. Chen, D. L.; Rosenbluth, D. B.; Mintun, M. A.; Schuster, D. P. FDG-PET imaging of pulmonary inflammation in healthy volunteers after airway instillation of endotoxin. J. Appl. Physiol. 2006, 100, 1602-1609.
24. Jones, H.; Cadwallader, K.; White, J.; Uddin, M.; Peters, A.; Chilvers, E. Dissociation between respiratory burst activity and deoxyglucose uptake in human neutrophil granulocytes: implications for interpretation of (18)F-FDG PET images. J. Nucl. Med. 2002, 43 (5), 652-657.
25. Chen, D. L.; Mintun, M. A.; Schuster, D. P. Comparison of methods to quantitate 18F-FDG uptake with PET during experimental acute lung injury. J. Nucl. Med. 2004, 45 (9), 1583-1590.
26. Schuster, D. P. ARDS: clinical lessons from the oleic acid model of acute lung injury. Am. J. Respir. Crit. Care Med. 1994, 149 (1), 245-260.
27. Gust, R.; Kozlowski, J.; Stephenson, A. H.; Schuster, D. P. Synergistic hemodynamic effects of low-dose endotoxin and acute lung injury. Am. J. Respir. Crit. Care Med. 1998, 157 (6 Pt 1), 1919-1926.
28. Lewis, P.; Salama, A. Uptake of fluorine-18-fluorodeoxyglucose in sarcoidosis. J. Nucl. Med. 1994, 35, 1647-1649.
29. Brudin, L. H.; Valind, S. O.; Rhodes, C. G.; Pantin, C. F.; Sweatman, M.; Jones, T.; Hughes, J. M. Fluorine-18 deoxyglucose uptake in sarcoidosis measured with positron emission tomography. Eur. J. Nucl. Med. 1994, 21 (4), 297-305.
30. Patlak, C. S.; Blasberg, R. G. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J. Cereb. Blood Flow Metab. 1985, 5 (4), 584-590.
31. Patlak, C. S.; Blasberg, R. G.; Fenstermacher, J. D. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J. Cereb. Blood Flow. Metab. 1983, 3 (1), 1-7.
32. Jones, H.; Sriskandan, S.; Peters, A.; Pride, N.; Krausz, T.; Boobis, A.; Haslett, C. Dissociation of neutrophil emigration and metabolic activity in lobar pneumonia and bronchiectasis. Eur. Respir. J. 1997, 10 (4), 795-803.
33. Jones, H. A.; Clark, R. J.; Rhodes, C. G.; Schofield, J. B.; Krausz, T.; Haslett, C. Positron emission tomography of 18FDG uptake in localized pulmonary inflammation. Acta Radiol., Suppl. 1991, No. 376, 148.
34. Rosenbluth, D. B.; Wilson, K.; Ferkol, T.; Schuster, D. P. Lung function decline in cystic fibrosis patients and timing for lung transplantation referral. Chest 2004, 126 (2), 412-419.
35. 18fluorodeoxyglucose in the cystic fibrosis lung: a measure of lung inflammation? Eur. Respir. J. 2003, 21, 848-854.
36. Taylor, I. H., AA.; Hayes, M.; Rhodes, C.; O'Shaughnessy, K.; O'Connor, B.; Jones, H.; Hughes, J.; Jones, T.; Pride, N.; Fuller, R. Imaging allergen-invoked airway inflammation in atopic asthma with [18F]- fluorodeoxyglucose and positron emission tomography. Lancet 1996, 347, 937-940.
37. O'Grady, N. P.; Preas, H. L.; Pugin, J.; Fiuza, C.; Tropea, M.; Reda, D.; Banks, S. M.; Suffredini, A. F. Local inflammatory responses following bronchial endotoxin instillation in humans. Am. J. Respir. Crit. Care Med. 2001, 163 (7), 1591-1598.
38. Russi, T. J.; Crystal, R. G., Use of bronchoalveolar lavage and airway brushing to investigate the human lung. In The Lung: Scientific Foundations, 2nd ed.; Crystal, R. G., West, J. B., Barnes, P. J., Weibel, E. R., Eds.; Lippincott-Raven Publications: Philadelphia, 1997; pp 371-382.
39. Konstan, M. W.; Milliard, K. A.; Norvell, T. M.; Berger, M. Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. Am. J. Respir. Crit. Care Med. 1994, 150, (2), 448-454.
40. Suffredini, A. F.; O'Grady, J. G., Pathophysiologial responses to endotoxin in humans. In Endotoxin in health and disease, 1st ed.; Braude, S., Opal, S. M., Vogel, S. N., Morrison, D. C., Eds.; Marcel Dekker: New York, 1999; pp 817-830.
41. Schultz, M.; Olszyna, D.; de Jonge, E.; Verbon, A.; van Devener, S.; van der Poll, T. Reduced ex vivo chemokine production by polymorphonuclear cells after in vivo exposure of normal humans to endotoxin. J. Infect. Dis. 2000, 182, 1264-1267.
42. Mullarkey, M.; Rose, J.; Bristol, J.; Kawata, T.; Kimura, A.; Kobayashi, S.; Przetak, M.; Chow, J.; Gusovsky, F.; Christ, W.; Rossignol, D. Inhibition of endotoxin response by E5564, a novel toll-like receptor 4-directed endotoxin antagonist. J. Pharmacol. Exp. Ther. 2003, 304, 1093-1102.
43. Wilson, M.; Blum, R.; Dandona, P.; Mousa, S. Effects in humans of intravenously administered endotoxin on soluble cell-adhesion molecule and inflammatory markers: a model of human diseases. Clin. Exp. Pharmacol. Physiol. 2001, 28 (5-6), 376-380.
44. Lorenz, E.; Jones, M.; Wohlford-Lenane, C.; Meyer, N.; Frees. K.; Arbour, N.; Schwartz, D. Genes other than TLR4 are involved in the response to inhaled LPS. Am. J. Physiol 2001, 281, L1106-L1114.
45. Hardwick, M. J.; Chen, M. K.; Baidoo, K.; Pomper, M. G.; Guilarte, T. R. In vivo imaging of peripheral benzodiazepine receptors in mouse lungs: a biomarker of inflammation. Mol. Imaging 2005, 4 (4), 432-438.
46. Jones, H. A.; Valind, S. O.; Clark, I. C.; Bolden, G. E.; Krausz, T.; Schofield, J. B.; Boobis, A. R.; Haslett, C. Kinetics of lung macrophages monitored in vivo following particulate challenge in rabbits. Toxicol. Appl. Pharmacol. 2002, 183 (1), 46-54.
47. Jones, H. A.; Marino, P. S.; Shakur, B. H.; Morrell, N. W. In vivo assessment of lung inflammatory cell activity in patients with COPD and asthma. Eur. Respir. J. 2003, 21 (4), 567-573.
48. Jones, H. A.; Harnacher, K.; Clark, J. C.; Schofield, J. B.; Krausz, T.; Haslett, C.; Boobis, A. R. Positron emission tomography in the quantification of cellular and biochemical responses to intrapulmonary particulates. Toxicol. Appl. Pharmacol. 2005, 207 (2 Suppl.), 230-236.